The presence of an aberrantly activated epidermal growth factor receptor (EGFR) in many
epithelial tumors, due to its overexpression, activating mutations, gene amplification and/or …

Aim: To clarify the correlation between serum levels of carcinoembryonic antigen (CEA) and
cytokeratin 19 fragment (CYFRA) and metastasis and survival in anaplastic lymphoma …

Background The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib has
failed in many ways to be as potent in the anti-cancer role as pre-clinical studies would have …

Background Recommended therapies for advanced/metastatic non-small cell lung cancer
(NSCLC) have changed with the advent of targeted therapies. The objectives of this …

The objective of this study was to evaluate the efficacy of epidermal growth factor receptor‑
tyrosine kinase inhibitors (EGFR‑TKIs) in patients undergoing dose reduction and in those …

The incidence and mortality of lung cancer have increased worldwide over the last decades,
with an observed increased incidence particularly among elderly populations. It has not yet …

Background/Aim: To describe real clinical outcomes when using systemic therapy to treat
non-small cell lung cancer (NSCLC) patients who have anaplastic lymphoma kinase (ALK) …

To evaluate the efficacy and safety of S‑1 monotherapy, S‑1‑containing combined
chemotherapy and S‑1 containing chemoradiotherapy for non‑small cell lung cancer …

Résumé De nombreux médicaments sont utilisés dans le traitement des cancers
pulmonaires. Leurs effets indésirables, variés et fréquents, peuvent être redoutables. Les …

We read with interest the report by Weiss and associates on comparative effectiveness and
resource usage in patients receiving first-line taxol-based chemotherapy for stage IV …